Tenet Healthcare's investors have seen a spectacular 604% return over the last five years.

Tenet Healthcare's investors have seen a 604% return over the last five years, with a 44% increase in the last quarter. The share price growth is attributed to the company's transition from a loss to profitability, with EPS up 21% per year over the last three years. However, the market has a higher opinion of the business than it did three years ago, as evidenced by the 177% share price growth in the last three years.

Tenet Healthcare Corporation (NYSE: THC) has experienced significant growth and positive analyst sentiment, making it a notable player in the healthcare sector. Over the past five years, the company's investors have witnessed a remarkable 604% return, with a 44% increase in the last quarter alone [1]. This impressive performance can be attributed to Tenet's transition from operating at a loss to achieving profitability, as evidenced by a 21% annual increase in earnings per share (EPS) over the last three years [1].

Analysts have taken notice of Tenet's financial turnaround, with nineteen research firms currently covering the company. These firms have assigned an average rating of "Moderate Buy" to THC, indicating optimism about the company's future prospects [1]. Among the analysts, three have recommended a hold, fifteen have suggested a buy, and one has given a strong buy recommendation [1]. The average 1-year price objective among these analysts is $185.41 [1].

Several prominent brokerages have also upgraded their ratings and price targets for Tenet. For instance, Barclays boosted their price objective from $171.00 to $215.00 and gave the company an "overweight" rating [1]. Stephens upgraded Tenet to a "strong-buy" rating [1]. Mizuho increased their price objective from $184.00 to $194.00 and gave the company an "outperform" rating [1]. Wall Street Zen upgraded Tenet from a "hold" rating to a "buy" rating [1]. Morgan Stanley upped their price target from $175.00 to $210.00 and gave the stock an "overweight" rating [1].

Institutional investors have also shown interest in Tenet, with several entities increasing their stakes in the company. Signaturefd LLC, State of Alaska Department of Revenue, Norden Group LLC, Counterpoint Mutual Funds LLC, and GAMMA Investing LLC all lifted their holdings in Tenet Healthcare during the second quarter [1].

Despite the positive analyst ratings and institutional inflows, Tenet's stock has faced some insider selling activity. Director James L. Bierman sold 13,836 shares, and Director Richard W. Fisher sold 3,077 shares, with both transactions occurring in May [1]. Over the last ninety days, insiders have sold a total of 54,121 shares of company stock worth $8,846,305 [1].

Tenet Healthcare's latest quarterly earnings data, announced on April 29th, showed a return on equity of 22.58% and a net margin of 7.09%. The company reported $4.36 EPS, exceeding analysts' consensus estimates of $3.11 by $1.25 [1]. Revenue for the quarter was $5.22 billion, down 2.5% on a year-over-year basis [1].

Looking ahead, analysts expect Tenet Healthcare to post 12.24 earnings per share for the current year. The company's upcoming earnings report is expected on July 22, 2025, with the EPS projected at $2.82, representing a 22.08% increase compared to the same quarter of the previous year [2]. The full-year Zacks Consensus Estimates call for earnings of $12.75 per share and revenue of $20.9 billion [2].

In conclusion, Tenet Healthcare Corporation has demonstrated strong financial performance and positive analyst sentiment, making it an attractive investment opportunity. However, investors should be mindful of recent insider selling activity and closely monitor the company's upcoming earnings report.

References:
[1] https://www.marketbeat.com/instant-alerts/tenet-healthcare-corporation-nysethc-receives-average-rating-of-moderate-buy-from-brokerages-2025-07-13/
[2] https://www.nasdaq.com/articles/tenet-healthcare-thc-rises-higher-market-key-facts-1